India To Weed Out Over 300 Fixed-Dose Combos; Next Round In Court
This article was originally published in Scrip
Executive Summary
India has clamped down on the country's burgeoning market for irrational fixed-dose combinations (FDCs), weeding out more than 300 such products – a move that is seen as denting the industry sharply but being welcomed by physicians given the lack of therapeutic rationale for most of these medicines and the growing challenge of drug resistance in the case of anti-infectives.
You may also be interested in...
Tweaked ‘New Drugs’ Flouted Price Approval Norms In India
Pharmaceutical firms face more flak in India for allegedly flouting pricing norms – this time more than 200 formulations were allegedly launched in the country without seeking price approvals, though some companies claim they are fully compliant with the norms.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet